Mechanism and treatment of short stature in children with nephrotic syndrome

doi:10.3877/cma.j.issn.2095-3216.2018.06.008

Abstract

Abstract:

Primary nephrotic syndrome (PNS) is a common kidney disease in children. The widespread use of glucocorticoids and other immunosuppressive agents has significantly improved the cure rate and survival rate of nephrotic syndrome patients. However, the complex pathophysiological mechanism of nephrotic syndrome and the long-term use of immunosuppressive agents such as glucocorticoids have led to the more prominent growth retardation in children with nephrotic syndrome, although the growth and development in childhood has an important influence on their heights at adult. There is no systematic and mature scheme for the prevention and treatment of short stature in children with PNS. The use of recombinant human growth hormone to treat short stature of children with PNS is currently the main means, but its safety and efficacy still need further researches for confirmation.

Key words: Nephrotic syndrome, Short stature, Mechanism, Treatment

Mei Lu, Chunlin Gao, Xiao Yang, Zhengkun Xia. Mechanism and treatment of short stature in children with nephrotic syndrome[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(06): 277-279.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2018.06.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2018/V07/I06/277

References 28

[12]	Ocaranza P, Lammoglia JJ, Iniguez G, et al. Effects of thyroid hormone on the GH signal transduction pathway [J]. Growth Horm IGF Res, 2014, 24(1): 42-46.
[13]	Rogol AD. Sex steroids, growth hormone, leptin and the pubertal growth spurt [J]. Endocr Dev, 2010, 17: 77-85.
[14]	de Lemos SG, Tirapegui J. Growth hormone secretion and nutrition [J]. Arq Gastroenterol, 1994, 31(4): 159-172.
[15]	易著文，刘建华. 原发性肾病综合征患儿生长激素－胰岛素样生长因子轴的变化与生长障碍[J]．中华儿科杂志，1999，37(4)：235.
[16]	Allen DB. Inhaled corticosteroids and growth: still an issue after all these years [J]. J Pediatr, 2015, 166(2): 463-469.
[17]	Altowati MA, Russell RK, Ahmed SF. Endocrine therapy for growth retardation in paediatric inflammatory bowel disease [J]. Paediatr Drugs, 2014, 16(1): 29-42.
[18]	Wolthers OD, Ramshanker N, Heuck C, et al. The timing of administration of exogenous glucocorticoid affects 24hour growth hormone secretion in children [J]. Growth Horm IGF Res, 2017, 35(1): 40-44.
[19]	Tsampalieros A, Gupta P, Denburg MR, et al. Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome [J]. J Bone Miner Res, 2013, 28(3): 480-488.
[20]	Ribeiro D, Zawadynski S, Pittet LF, et al. Effect of glucocorticoids on growth and bone mineral density in children with nephrotic syndrome [J]. Eur J Pediatr, 2015, 174(7): 911-917.
[21]	Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy [J]. Physiol Rev, 2016, 96(2): 409-447.
[22]	Simmonds J, Grundy N, Trompeter R, et al. Long－term steroid treatment and growth: a study in steroid－dependent nephrotic syndrome [J]. Arch Dis Child, 2010, 95(2): 146-149.
[23]	Skrzypczyk P, Panczyk－Tomaszewska M, Roszkowska－Blaim M, et al. Long－term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood [J]. Clin Nephrol, 2014, 81(3): 166-173.
[24]	Marimuthu V, Krishnamurthy S, Rajappa M. Non－autoimmune subclinical and overt hypothyroidism in idiopathic steroid－resistant nephrotic syndrome in children [J]. Indian Pediatr, 2017, 54(11): 925-929.
[25]	Mehlman CT, Ain MC. Evaluation of the child with short stature [J]. Orthop Clin North Am, 2015, 46(4): 523-531.
[26]	Allen DB, Backeljauw P, Bidlingmaier M, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults [J]. Eur J Endocrinol, 2016, 174(2): P1-P9.
[1]	中华医学会儿科学分会肾脏学组．儿童激素敏感、复发/依赖肾病综合征诊治循证指南(2016)[J]．中华儿科杂志，2017，(10)：729-734.
[2]	中华医学会儿科学分会肾脏学组．激素耐药型肾病综合征诊治循证指南(2016)[J]．中华儿科杂志，2017，(11)：805-809.
[3]	Hjorten R, Anwar Z, Reidy KJ. Long－term outcomes of childhood onset nephrotic syndrome [J]. Front Pediatr, 2016, 4: 53.
[4]	Donatti TL, Koch VH. Final height of adults with childhood－onset steroid－responsive idiopathic nephrotic syndrome [J]. Pediatr Nephrol, 2009, 24(12): 2401-2408.
[5]	闫洁．儿童矮身材诊治进展[J]．中华实用儿科临床杂志，2016，(23)：1778-1782.
[6]	Saenger PH, Mejia－Corletto J. Long－acting growth hormone: an update [J]. Endocr Dev, 2016, 30: 79-97.
[7]	Kanaley JA. Growth hormone, arginine and exercise [J]. Curr Opin Clin Nutr Metab Care, 2008, 11(1): 50-54.
[8]	Tritos NA, Biller BM. Growth hormone and bone [J]. Curr Opin Endocrinol Diabetes Obes, 2009, 16(6): 415-422.
[9]	Rosen CJ. Growth hormone and aging [J]. Endocrine, 2000, 12(2): 197-201.
[10]	Chinoy A, Murray PG. Diagnosis of growth hormone deficiency in the paediatric and transitional age [J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(6): 737-747.
[11]	Pascual A, Aranda A. Thyroid hormone receptors, cell growth and differentiation [J]. Biochim Biophys Acta, 2013, 1830(7): 3908-3916.
[27]	Loke KY, Yap HK, Zhou X, et al. Efficacy and safety of one year of growth hormone therapy in steroid－dependent nephrotic syndrome [J]. J Pediatr, 1997, 130(5): 793-799.
[28]	Sato M, Ito S, Ogura M, et al. Impact of rituximab on height and weight in children with refractory steroid－dependent nephrotic syndrome [J]. Pediatr Nephrol, 2014, 29(8): 1373-1379.

Please choose a citation manager

Content to export